Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk.

OBJECTIVES - To evaluate the ability of the Decipher genomic classifier in predicting metastasis from analysis of prostate needle biopsy diagnostic tumor tissue specimens.

METHODS - Fifty-seven patients with available biopsy specimens were identified from a cohort of 169 men treated with RP in a previously reported Decipher validation study at Cleveland Clinic.

Cox multivariable (MVA) proportional hazards model and survival c-index were used to evaluate the performance of Decipher.

RESULTS - With a median follow up of 8 years, 8 patients metastasized and 3 died of PCa. Decipher plus NCCN model had an improved c-index of 0. 88 (95% confidence interval [CI] 0. 77-0. 96) compared to NCCN alone (c-index 0. 75; 95% CI 0. 64-0. 87). On MVA, Decipher was the only significant predictor of metastasis when adjusting for age, preoperative PSA and biopsy Gleason score (Decipher hazard ratio per 10% increase 1. 72; 95% CI 1. 07-2. 81; P = 0. 02).

CONCLUSIONS - Biopsy-based Decipher predicted the risk of metastasis at 10 years post-RP. While further validation is required on larger cohorts, pre-operative knowledge of Decipher risk derived from biopsy could indicate the need for multimodality therapy and help set patient expectations of therapeutic burden.

Urology. 2016 Jan 22 [Epub ahead of print]

Eric A Klein, Zaid Haddad, Kasra Yousefi, Lucia L Lam, Qiqi Wang, Voleak Choeurng, Beatrix Palmer-Aronsten, Christine Buerki, Elai Davicioni, Jianbo Li, Michael W Kattan, Andrew J Stephenson, Cristina Magi-Galluzzi

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. GenomeDx Biosciences Inc, Vancouver, BC, Canada. , GenomeDx Biosciences Inc, Vancouver, BC, Canada. , GenomeDx Biosciences Inc, Vancouver, BC, Canada. , GenomeDx Biosciences Inc, Vancouver, BC, Canada. , GenomeDx Biosciences Inc, Vancouver, BC, Canada. , GenomeDx Biosciences Inc, Vancouver, BC, Canada. , GenomeDx Biosciences Inc, Vancouver, BC, Canada. , GenomeDx Biosciences Inc, Vancouver, BC, Canada. , Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA. , Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA. , Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. , Anatomic Pathology, Cleveland Clinic, Cleveland, OH, USA.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe